Skip to main
CERE
CERE logo

CERE Stock Forecast & Price Target

CERE Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 20%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Cerevel Therapeutics Hldg is poised for success with its differentiated approach to treating neuroscience diseases and its strong portfolio of investigational therapies. The recent acquisition by AbbVie further solidifies Cerevel's position as a leader in this space. With a diverse pipeline and promising results from its clinical trials, Cerevel has the potential for significant growth and is a strong investment opportunity for those interested in the neuroscience sector.

Bears say

Cerevel Therapeutics Hldg is facing significant challenges with a recent downgrade and price target of $45 due to an acquisition by AbbVie. The company's DCF model suggests a decline rate of 10% and a discount rate of 8.3%, which indicates a low valuation of their assets. Additionally, past clinical studies for their investigational therapies have been halted, raising concerns about potential safety and tolerability issues. With limited potential for other suitors and the deal with AbbVie likely to close, there are several uncertainties surrounding Cerevel's future prospects.

CERE has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 20% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cerevel Therapeutics Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cerevel Therapeutics Holdings Inc (CERE) Forecast

Analysts have given CERE a Hold based on their latest research and market trends.

According to 15 analysts, CERE has a Hold consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cerevel Therapeutics Holdings Inc (CERE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.